NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT05054725 2026-01-06Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesRevolution Medicines, Inc.Phase 2 Completed47 enrolled 17 charts
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT01199068 2021-05-13CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)Daiichi SankyoPhase 1 Completed15 enrolled 14 charts
NCT01199055 2020-07-07CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)Daiichi SankyoPhase 1 Completed16 enrolled 14 charts